Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott D Larsen

Showing results (71-80 of 86) with videos related to

Pageof 9
Sort By:
Bioorganic & Medicinal Chemistry Letters|December 8, 2007
Substituted oxazolidinones as novel NPC1L1 ligands for the inhibition of cholesterol absorptionJeffrey A Pfefferkorn, Scott D Larsen, Chad Van Huis, et al.
Bioorganic & Medicinal Chemistry Letters|September 4, 2007
Pyrazole inhibitors of HMG-CoA reductase: an attempt to dramatically reduce synthetic complexity through minimal analog re-designScott D Larsen, Toni-Jo Poel, Kevin J Filipski, et al.
Journal of Medicinal Chemistry|April 6, 2019
5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for SclerodermaDylan J Kahl, Kim M Hutchings, Erika Mathes Lisabeth, et al.
European Journal of Medicinal Chemistry|December 20, 2020
Development of 2,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of aldehyde dehydrogenase 1A (ALDH1A) as potential adjuncts to ovarian cancer chemotherapyBrandt C Huddle, Edward Grimley, Mikhail Chtcherbinine, et al.
The American Journal of Pathology|February 15, 2015
Inhibition of myocardin-related transcription factor/serum response factor signaling decreases lung fibrosis and promotes mesenchymal cell apoptosisThomas H Sisson, Iyabode O Ajayi, Natalya Subbotina, et al.
Nature Communications|October 14, 2016
Structure-mechanism-based engineering of chemical regulators targeting distinct pathological factors in Alzheimer's diseaseMichael W Beck, Jeffrey S Derrick, Richard A Kerr, et al.
Journal of Medicinal Chemistry|December 13, 2007
Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hypercholesterolemiaJeffrey A Pfefferkorn, Chulho Choi, Scott D Larsen, et al.
Bioorganic & Medicinal Chemistry Letters|March 14, 2017
Pharmacokinetic optimitzation of CCG-203971: Novel inhibitors of the Rho/MRTF/SRF transcriptional pathway as potential antifibrotic therapeutics for systemic sclerodermaKim M Hutchings, Erika M Lisabeth, Walajapet Rajeswaran, et al.
Bioorganic & Medicinal Chemistry Letters|December 25, 2007
Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitorsWilliam K C Park, Robert M Kennedy, Scott D Larsen, et al.
Journal of Biomolecular Screening|August 17, 2011
Complementary cell-based high-throughput screens identify novel modulators of the unfolded protein responseAndrew M Fribley, Patricia G Cruz, Justin R Miller, et al.
Pageof 9

Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
Bioorganic & Medicinal Chemistry Letters|December 8, 2007
Substituted oxazolidinones as novel NPC1L1 ligands for the inhibition of cholesterol absorptionJeffrey A Pfefferkorn, Scott D Larsen, Chad Van Huis, et al.
Bioorganic & Medicinal Chemistry Letters|September 4, 2007
Pyrazole inhibitors of HMG-CoA reductase: an attempt to dramatically reduce synthetic complexity through minimal analog re-designScott D Larsen, Toni-Jo Poel, Kevin J Filipski, et al.
Journal of Medicinal Chemistry|April 6, 2019
5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for SclerodermaDylan J Kahl, Kim M Hutchings, Erika Mathes Lisabeth, et al.
European Journal of Medicinal Chemistry|December 20, 2020
Development of 2,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of aldehyde dehydrogenase 1A (ALDH1A) as potential adjuncts to ovarian cancer chemotherapyBrandt C Huddle, Edward Grimley, Mikhail Chtcherbinine, et al.
The American Journal of Pathology|February 15, 2015
Inhibition of myocardin-related transcription factor/serum response factor signaling decreases lung fibrosis and promotes mesenchymal cell apoptosisThomas H Sisson, Iyabode O Ajayi, Natalya Subbotina, et al.
Nature Communications|October 14, 2016
Structure-mechanism-based engineering of chemical regulators targeting distinct pathological factors in Alzheimer's diseaseMichael W Beck, Jeffrey S Derrick, Richard A Kerr, et al.
Journal of Medicinal Chemistry|December 13, 2007
Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hypercholesterolemiaJeffrey A Pfefferkorn, Chulho Choi, Scott D Larsen, et al.
Bioorganic & Medicinal Chemistry Letters|March 14, 2017
Pharmacokinetic optimitzation of CCG-203971: Novel inhibitors of the Rho/MRTF/SRF transcriptional pathway as potential antifibrotic therapeutics for systemic sclerodermaKim M Hutchings, Erika M Lisabeth, Walajapet Rajeswaran, et al.
Bioorganic & Medicinal Chemistry Letters|December 25, 2007
Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitorsWilliam K C Park, Robert M Kennedy, Scott D Larsen, et al.
Journal of Biomolecular Screening|August 17, 2011
Complementary cell-based high-throughput screens identify novel modulators of the unfolded protein responseAndrew M Fribley, Patricia G Cruz, Justin R Miller, et al.
Pageof 9